A Multi-Country Real-World Evidence Study Characterising Patients and Abemaciclib Persistence at 6 months of Treatment in HR+, HER2- High-Risk Early Breast Cancer (Abema EBC).

ESTUDIO OBSERVACIONAL CON MEDICAMENTOS